{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:40:09Z","timestamp":1793659209064,"version":"4.5.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Keio University Medical Science Fund"},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"crossref","award":["JP23K15313"],"award-info":[{"award-number":["JP23K15313"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"crossref","award":["JP21H05051"],"award-info":[{"award-number":["JP21H05051"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Center Research and Development Funds","award":["30-A-1"],"award-info":[{"award-number":["30-A-1"]}]},{"name":"Japan Science and Technology Agency Moonshot R&D Program","award":["JPMJMS2022"],"award-info":[{"award-number":["JPMJMS2022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01397-y","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:36:22Z","timestamp":1775324182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of gene fusion detection algorithms reveals frequently overlooked driver fusions in hematologic malignancies"],"prefix":"10.1038","volume":"10","author":[{"given":"Zen","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Oshikawa-Kumade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumito","family":"Shingaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kariyazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Kikukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotoe","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"1397_CR1","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41586-025-08817-2","volume":"640","author":"AE Kamizela","year":"2025","unstructured":"Kamizela, A. E. et al. Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia. Nature 640, 982\u2013990 (2025).","journal-title":"Nature"},{"key":"1397_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ng.3230","volume":"47","author":"AK Andersson","year":"2015","unstructured":"Andersson, A. K. et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 47, 330\u2013337 (2015).","journal-title":"Nat. Genet."},{"key":"1397_CR3","unstructured":"WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. 5th edn, (International Agency for Research on Cancer, 2024)."},{"key":"1397_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"1397_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","volume":"37","author":"K Mrozek","year":"2023","unstructured":"Mrozek, K. et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia 37, 788\u2013798 (2023).","journal-title":"Leukemia"},{"key":"1397_CR6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa, G. C. et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615, 920\u2013924 (2023).","journal-title":"Nature"},{"key":"1397_CR7","unstructured":"Issa, G. C. et al. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J. Clin. Oncol. 43, 75\u201384 (2025)."},{"key":"1397_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang, E. S. et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 25, 1310\u20131324 (2024).","journal-title":"Lancet Oncol."},{"key":"1397_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nri2304","volume":"8","author":"I Aifantis","year":"2008","unstructured":"Aifantis, I., Raetz, E. & Buonamici, S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat. Rev. Immunol. 8, 380\u2013390 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1397_CR10","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1002\/j.1460-2075.1990.tb07535.x","volume":"9","author":"L Brown","year":"1990","unstructured":"Brown, L. et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J. 9, 3343\u20133351 (1990).","journal-title":"EMBO J."},{"key":"1397_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1158\/2159-8290.CD-23-0902","volume":"14","author":"S Horie","year":"2024","unstructured":"Horie, S. et al. Pan-cancer comparative and integrative analyses of driver alterations using japanese and international genomic databases. Cancer Discov. 14, 786\u2013803 (2024).","journal-title":"Cancer Discov."},{"key":"1397_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrc3947","volume":"15","author":"F Mertens","year":"2015","unstructured":"Mertens, F., Johansson, B., Fioretos, T. & Mitelman, F. The emerging complexity of gene fusions in cancer. Nat. Rev. Cancer 15, 371\u2013381 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1397_CR13","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","volume":"127","author":"J He","year":"2016","unstructured":"He, J. et al. Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting. Blood 127, 3004\u20133014 (2016).","journal-title":"Blood"},{"key":"1397_CR14","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/cas.13968","volume":"110","author":"S Kohsaka","year":"2019","unstructured":"Kohsaka, S. et al. Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. Cancer Sci. 110, 1464\u20131479 (2019).","journal-title":"Cancer Sci."},{"key":"1397_CR15","doi-asserted-by":"crossref","unstructured":"Fukuhara, S. et al. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci. 113, 2763\u20132777 (2022).","DOI":"10.1111\/cas.15427"},{"key":"1397_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-S7-S2","volume":"14","author":"M Carrara","year":"2013","unstructured":"Carrara, M. et al. State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues?. BMC Bioinform. 14, S2 (2013).","journal-title":"BMC Bioinform."},{"key":"1397_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep21597","volume":"6","author":"S Kumar","year":"2016","unstructured":"Kumar, S., Vo, A. D., Qin, F. & Li, H. Comparative assessment of methods for the fusion transcripts detection from RNA-Seq data. Sci. Rep. 6, 21597 (2016).","journal-title":"Sci. Rep."},{"key":"1397_CR18","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv1234","volume":"44","author":"S Liu","year":"2016","unstructured":"Liu, S. et al. Comprehensive evaluation of fusion transcript detection algorithms and a meta-caller to combine top performing methods in paired-end RNA-seq data. Nucleic Acids Res. 44, e47 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1397_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1842-9","volume":"20","author":"BJ Haas","year":"2019","unstructured":"Haas, B. J. et al. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 20, 213 (2019).","journal-title":"Genome Biol."},{"key":"1397_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cels.2021.05.021","volume":"12","author":"A Creason","year":"2021","unstructured":"Creason, A. et al. A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery. Cell Syst. 12, 827\u2013838. e825 (2021).","journal-title":"Cell Syst."},{"key":"1397_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41586-020-1970-0","volume":"578","author":"PCAWG Transcriptome Core Group","year":"2020","unstructured":"PCAWG Transcriptome Core Group et al. Genomic basis for RNA alterations in cancer. Nature 578, 129\u2013136 (2020).","journal-title":"Nature"},{"key":"1397_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1101\/gr.257246.119","volume":"31","author":"S Uhrig","year":"2021","unstructured":"Uhrig, S. et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 31, 448\u2013460 (2021).","journal-title":"Genome Res."},{"key":"1397_CR23","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/bioinformatics\/bts617","volume":"28","author":"M Benelli","year":"2012","unstructured":"Benelli, M. et al. Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript. Bioinformatics 28, 3232\u20133239 (2012).","journal-title":"Bioinformatics"},{"key":"1397_CR24","doi-asserted-by":"publisher","unstructured":"Nicorici, D. et al. FusionCatcher\u2014a tool for finding somatic fusion genes in paired-end RNA-sequencing data. bioRxiv, 011650, https:\/\/doi.org\/10.1101\/011650 (2014).","DOI":"10.1101\/011650"},{"key":"1397_CR25","doi-asserted-by":"publisher","first-page":"e114263","DOI":"10.1371\/journal.pone.0114263","volume":"9","author":"Y Shiraishi","year":"2014","unstructured":"Shiraishi, Y. et al. Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers. PLoS One 9, e114263 (2014).","journal-title":"PLoS One"},{"key":"1397_CR26","doi-asserted-by":"publisher","first-page":"e0167417","DOI":"10.1371\/journal.pone.0167417","volume":"11","author":"K Okonechnikov","year":"2016","unstructured":"Okonechnikov, K. et al. InFusion: advancing discovery of fusion genes and chimeric transcripts from deep RNA-sequencing data. PLoS One 11, e0167417 (2016).","journal-title":"PLoS One"},{"key":"1397_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0167-x","volume":"7","author":"NM Davidson","year":"2015","unstructured":"Davidson, N. M., Majewski, I. J. & Oshlack, A. JAFFA: high sensitivity transcriptome-focused fusion gene detection. Genome Med 7, 43 (2015).","journal-title":"Genome Med"},{"key":"1397_CR28","doi-asserted-by":"publisher","unstructured":"Melsted, P. et al. Fusion detection and quantification by pseudoalignment. bioRxiv, 166322, https:\/\/doi.org\/10.1101\/166322 (2017).","DOI":"10.1101\/166322"},{"key":"1397_CR29","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1093\/bioinformatics\/bty091","volume":"34","author":"NK Akers","year":"2018","unstructured":"Akers, N. K., Schadt, E. E. & Losic, B. STAR Chimeric Post for rapid detection of circular RNA and fusion transcripts. Bioinformatics 34, 2364\u20132370 (2018).","journal-title":"Bioinformatics"},{"key":"1397_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3535","volume":"48","author":"T Yasuda","year":"2016","unstructured":"Yasuda, T. et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat. Genet. 48, 569\u2013574 (2016).","journal-title":"Nat. Genet."},{"key":"1397_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2141.2004.05048.x","volume":"126","author":"D Intini","year":"2004","unstructured":"Intini, D. et al. Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation. Br. J. Haematol. 126, 437\u2013439 (2004).","journal-title":"Br. J. Haematol."},{"key":"1397_CR32","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1126\/science.2255914","volume":"250","author":"PD Aplan","year":"1990","unstructured":"Aplan, P. D. et al. Disruption of the human SCL locus by \u201cillegitimate\u201d V-(D)-J recombinase activity. Science 250, 1426\u20131429 (1990).","journal-title":"Science"},{"key":"1397_CR33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.leukres.2009.06.020","volume":"34","author":"S Nagel","year":"2010","unstructured":"Nagel, S. et al. Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. Leuk. Res 34, 521\u2013528 (2010).","journal-title":"Leuk. Res"},{"key":"1397_CR34","first-page":"91","volume":"15","author":"E Kjeldsen","year":"2018","unstructured":"Kjeldsen, E. et al. Characterization of camptothecin-induced genomic changes in the camptothecin-resistant T-ALL-derived cell line CPT-K5. Cancer Genomics Proteom. 15, 91\u2013114 (2018).","journal-title":"Cancer Genomics Proteom."},{"key":"1397_CR35","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1182\/blood-2003-07-2479","volume":"103","author":"J Cools","year":"2004","unstructured":"Cools, J. et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 103, 2802\u20132805 (2004).","journal-title":"Blood"},{"key":"1397_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood.V65.1.21.21","volume":"65","author":"RC Stong","year":"1985","unstructured":"Stong, R. C., Korsmeyer, S. J., Parkin, J. L., Arthur, D. C. & Kersey, J. H. Human acute leukemia cell line with the t(4; 11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 65, 21\u201331 (1985).","journal-title":"Blood"},{"key":"1397_CR37","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","volume":"92","author":"M Chesi","year":"1998","unstructured":"Chesi, M. et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts. Blood 92, 3025\u20133034 (1998).","journal-title":"Blood"},{"key":"1397_CR38","first-page":"4058","volume":"60","author":"U Malgeri","year":"2000","unstructured":"Malgeri, U. et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res. 60, 4058\u20134061 (2000).","journal-title":"Cancer Res."},{"key":"1397_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0165-4608(98)00157-5","volume":"109","author":"J Kuipers","year":"1999","unstructured":"Kuipers, J. et al. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet. Cytogenet. 109, 99\u2013107 (1999).","journal-title":"Cancer Genet. Cytogenet."},{"key":"1397_CR40","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2008.287","volume":"22","author":"J Gotlib","year":"2008","unstructured":"Gotlib, J. & Cools, J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22, 1999\u20132010 (2008).","journal-title":"Leukemia"},{"key":"1397_CR41","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1249484","volume":"343","author":"JN Honeyman","year":"2014","unstructured":"Honeyman, J. N. et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343, 1010\u20131014 (2014).","journal-title":"Science"},{"key":"1397_CR42","doi-asserted-by":"publisher","first-page":"13076","DOI":"10.1073\/pnas.1716483114","volume":"114","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber, E. R. et al. DNAJB1-PRKACA fusion kinase interacts with beta-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 114, 13076\u201313084 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1397_CR43","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-12-0042","volume":"2","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Discov. 2, 598\u2013607 (2012).","journal-title":"Cancer Discov."},{"key":"1397_CR44","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature11282","volume":"488","author":"S Seshagiri","year":"2012","unstructured":"Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660\u2013664 (2012).","journal-title":"Nature"},{"key":"1397_CR45","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/ng.936","volume":"43","author":"AJ Bass","year":"2011","unstructured":"Bass, A. J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 43, 964\u2013968 (2011).","journal-title":"Nat. Genet."},{"key":"1397_CR46","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1158\/1078-0432.CCR-18-1052","volume":"24","author":"MA Davare","year":"2018","unstructured":"Davare, M. A. et al. Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma. Clin. Cancer Res. 24, 6471\u20136482 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1397_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4116","volume":"5","author":"T Wiesner","year":"2014","unstructured":"Wiesner, T. et al. Kinase fusions are frequent in Spitz tumours and Spitzoid melanomas. Nat. Commun. 5, 3116 (2014).","journal-title":"Nat. Commun."},{"key":"1397_CR48","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.19.00261","volume":"37","author":"R Pieters","year":"2019","unstructured":"Pieters, R. et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study. J. Clin. Oncol. 37, 2246\u20132256 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1397_CR49","first-page":"3853","volume":"53","author":"JM Hilden","year":"1993","unstructured":"Hilden, J. M., Chen, C. S., Moore, R., Frestedt, J. & Kersey, J. H. Heterogeneity in MLL\/AF-4 fusion messenger RNA detected by the polymerase chain reaction in t(4;11) acute leukemia. Cancer Res. 53, 3853\u20133856 (1993).","journal-title":"Cancer Res."},{"key":"1397_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/sj.leu.2403236","volume":"18","author":"HG Drexler","year":"2004","unstructured":"Drexler, H. G., Quentmeier, H. & MacLeod, R. A. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia 18, 227\u2013232 (2004).","journal-title":"Leukemia"},{"key":"1397_CR51","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/sj.leu.2404800","volume":"21","author":"AK Stewart","year":"2007","unstructured":"Stewart, A. K. et al. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia 21, 2358\u20132359 (2007).","journal-title":"Leukemia"},{"key":"1397_CR52","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127, 2955\u20132962 (2016).","journal-title":"Blood"},{"key":"1397_CR53","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood.2022016212","volume":"141","author":"N Stong","year":"2023","unstructured":"Stong, N. et al. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood 141, 1574\u20131583 (2023).","journal-title":"Blood"},{"key":"1397_CR54","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1158\/0008-5472.CAN-21-1222","volume":"82","author":"M Carrabotta","year":"2022","unstructured":"Carrabotta, M. et al. Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma. Cancer Res. 82, 708\u2013720 (2022).","journal-title":"Cancer Res."},{"key":"1397_CR55","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2005-03-1283","volume":"106","author":"M Thomas","year":"2005","unstructured":"Thomas, M. et al. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 106, 3559\u20133566 (2005).","journal-title":"Blood"},{"key":"1397_CR56","first-page":"e1207","volume":"2","author":"D Ragusa","year":"2019","unstructured":"Ragusa, D. et al. The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features. Cancer Rep. 2, e1207 (2019).","journal-title":"Cancer Rep."},{"key":"1397_CR57","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao, Q. et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 23, 227\u2013238. e223 (2018).","journal-title":"Cell Rep."},{"key":"1397_CR58","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/ng.3691","volume":"48","author":"J Zhang","year":"2016","unstructured":"Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat. Genet. 48, 1481\u20131489 (2016).","journal-title":"Nat. Genet."},{"key":"1397_CR59","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/gcc.22454","volume":"56","author":"YC Kao","year":"2017","unstructured":"Kao, Y. C. et al. ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements. Genes Chromosomes Cancer 56, 501\u2013510 (2017).","journal-title":"Genes Chromosomes Cancer"},{"key":"1397_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2009-10-10-r115","volume":"10","author":"JZ Levin","year":"2009","unstructured":"Levin, J. Z. et al. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol. 10, R115 (2009).","journal-title":"Genome Biol."},{"key":"1397_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09374-9","volume":"10","author":"EE Heyer","year":"2019","unstructured":"Heyer, E. E. et al. Diagnosis of fusion genes using targeted RNA sequencing. Nat. Commun. 10, 1388 (2019).","journal-title":"Nat. Commun."},{"key":"1397_CR62","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMp1607591","volume":"375","author":"RL Grossman","year":"2016","unstructured":"Grossman, R. L. et al. Toward a shared vision for cancer genomic data. N. Engl. J. Med. 375, 1109\u20131112 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1397_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10637-8","volume":"10","author":"L Tian","year":"2019","unstructured":"Tian, L. et al. Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia. Nat. Commun. 10, 2789 (2019).","journal-title":"Nat. Commun."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01397-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:04:38Z","timestamp":1780445078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01397-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01397-y","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Kogure has received honoraria from Daiichi Sankyo, Nippon Shinyaku, Kyowa Kirin, and Takeda. Y.O.-K. is an employee of Otsuka Pharmaceutical Co., Ltd. S.F. has received honoraria from AstraZeneca, Ono Pharmaceutical, Chugai, Janssen, Otsuka Pharmaceutical Co., Ltd., AbbVie, Takeda, Genmab, Nihon Shinyaku, and Amgen; and has received research funding from Chugai, LOXO Oncology, AbbVie, and Mitsubishi Tanabe. H.K. is an employee of Otsuka Pharmaceutical Co., Ltd. Y. Kikukawa is an employee of Otsuka Pharmaceutical Co., Ltd. K.I. has received honoraria from Astra Zeneca, Ono Pharmaceutical, Eisai, Chugai, Janssen, Symbio, Bristol Myers Squibb, Daiichi Sankyo, Otsuka Pharmaceutical Co., Ltd., AbbVie, Takeda, Eli Lilly, Genmab, Kyowa Kirin, MSD, Pfizer, Meiji Seika Pharma, Novartis, Nihon Shinyaku, and Gilead\/Kite Pharma; has received research funding from MSD, AstraZeneca, AbbVie, Incyte, Symbio, Bristol Myers Squibb, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Daiichi Sankyo, Chugai, Beigene, Genmab, LOXO Oncology, Otsuka Pharmaceutical Co., Ltd., Regeneron, and Gilead\/Kite Pharma; and has received consultancy fees from Ono Pharmaceutical, Mitsubishi Tanabe Pharma, Eisai, Chugai, Symbio, Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., AbbVie, Takeda, Zenyaku, Genmab, Kyowa Kirin, MSD, Carna Biosciences, and Nihon Shinyaku. K. Kataoka has received honoraria from Ono Pharmaceutical, Eisai, Astellas Pharma, Novartis, Chugai, AstraZeneca, Sumitomo Dainippon Pharma, Kyowa Kirin, Janssen, MSD, Takeda, Symbio, Bristol Myers Squibb, Pfizer, Nippon Shinyaku, Daiichi Sankyo, Alexion Pharmaceuticals, AbbVie, Meiji Seika Pharma, Sanofi, Sysmex, Mundipharma, Incyte Corporation, Kyorin Pharmaceutical, PharmaEssentia Japan, Gilead Sciences, Kowa, Amgen, Nippon Kayaku, and Asahi Kasei Pharma; has received research funding from Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin, Takeda, Chugai, Chordia Therapeutics, Genmab, Bristol Myers Squibb, and Regeneron; has received consultancy fees from Meiji Seika Pharma and Otsuka Pharmaceutical Co., Ltd.; has received scholarship endowments from Asahi Kasei Pharma, Eisai, Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin, Shionogi, Daiichi Sankyo, Takeda, Sumitomo Dainippon Pharma, Chugai, Teijin Pharma, Japan Blood Products Organization, Mochida Pharmaceutical, JCR Pharmaceuticals, Nippon Shinyaku, and Nippon Kayaku; holds a patent to genetic alterations as a biomarker in T-cell lymphomas and a patent to PD-L1 abnormalities as a predictive biomarker for immune checkpoint blockade therapy; and holds stock in Asahi Genomics. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}